Altre lingue Black Diamond Therapeutics, Inc.

Azioni

BDTX

US09203E1055

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
5,89 ^USD	+15,26%		+11,98%	+109,61%

11/04	Black Diamond Therapeutics, Inc. annuncia cambiamenti nel Consiglio di Amministrazione e nel Comitato	CI
08/04	BLACK DIAMOND THERAPEUTICS, INC. : prospettiva positiva di Wedbush	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes	11/04
Black Diamond Therapeutics Announces Changes to Board of Directors	11/04
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients	08/04
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting	08/04
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting	08/04
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	03/04
Black Diamond: Q4 Earnings Snapshot	12/03
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12/03
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12/03
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024	05/03
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board	18/01
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones	04/01
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones	04/01
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM	13/12
Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM	13/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Black Diamond Therapeutics, Inc.

Azioni

BDTX

US09203E1055

Altre lingue

Filtri